Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Taranabant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 20/20 | 1.00 |
| ▸ | CNR2 | P34972 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taranabant SCHEMBL17565778 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL13253304 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL501972 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL29434856 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL304925 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL13253294 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3474367 | 0.95 | CNR1 (0.90) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3474366 | 0.95 | CNR1 (0.90) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3475455 | 0.93 | CNR1 (0.87) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL16357820 | 0.93 | CNR1 (0.87) | CNR1CNR2CYP2D6CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064199-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | claimed |
| WO-2008032156-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | claimed |
| EP-2582709-B1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI SA (FR) | 2018-01-24 | — | — | EP | disclosed |
| EP-2847191-B1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-06-15 | — | — | EP | disclosed |
| EP-2766349-B1 | OXATHIAZINE DERIVATIVES SUBSTITUTED WITH CARBOCYCLES OR HETEROCYCLES, METHOD FOR PRODUCING SAME, DRUGS CONTAINING SAID COMPOUNDS, AND USE THEREOF | SANOFI SA (FR) | 2016-06-01 | — | — | EP | disclosed |
| EP-2771340-B1 | 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-04-13 | — | — | EP | disclosed |
| EP-2760862-B1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2015-10-21 | — | — | EP | disclosed |
| EP-2683699-B1 | DI- AND TRI-SUBSTITUTED OXATHIAZINE DERIVATES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF | SANOFI SA (FR) | 2015-06-24 | — | — | EP | disclosed |
| EP-2683700-B1 | TETRA-SUBSTITUTED OXATHIAZINE DERIVATIVES, METHOD FOR THEIR PREPARATION, THEIR USAGE AS MEDICAMENT AND MEDICAMENT CONTAINING SAME AND ITS USE | SANOFI SA (FR) | 2015-02-18 | — | — | EP | disclosed |
| EP-2683704-B1 | BRANCHED OXATHIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF | SANOFI SA (FR) | 2014-12-17 | — | — | EP | disclosed |
| WO-2011161030-A1 | HETEROCYCLIC SUBSTITUTED METHOXYPHENYL DERIVATIVES HAVING AN OXO GROUP, METHOD FOR PRODUCING SAME, AND USE THEREOF AS GPR40 RECEPTOR MODULATORS | SANOFI (FR) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011157827-A1 | AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES | SANOFI (FR) | 2011-12-22 | — | — | WO | disclosed |
| US-20110207738-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-08-25 | — | — | US | disclosed |
| US-20110207738-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-08-25 | — | — | US | disclosed |
| WO-2010092153-A1 | NEW SUBSTITUTED TETRAHYDRONAPTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010092154-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
| WO-2009149820-A1 | ANNELATED N-HETEROCYCLIC SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009100936-A2 | NOVEL AROMATIC FLUOROGLYCOSIDE DERIVATIVES, PHARMACEUTICALS COMPRISING SAID COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009021740-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFIS-AVENTIS (FR) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | CNR1 13/4885CNR2 20/4885CYP2D6 154/4885 |
| US-20110207738-A1 | ANNELATED PYRROLIDIN SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | PPARD, PPARA, PPARG | CNR1 894/4885CNR2 637/4885CYP2D6 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.